查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587563

特发性肺纤维化治疗市场规模、份额、趋势分析报告：按药物类别、给药途径、分销管道、地区和细分市场预测，2025-2030 年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

特发性肺纤维化治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球特发性肺纤维化治疗市场规模预计将达到54.6亿美元，2025年至2030年复合年增长率为6.8%。

公司加强研发倡议以及吸烟人口的快速增加预计将推动成长。

製造商采取更多倡议来开发具有新颖机制的产品，预计将推动 IPF 治疗市场的成长。例如，Fibrogen 目前正在开发 pamrevlumumab，这是一种针对结缔组织生长因子的单株抗体。 pamrevlumumab 的 III 期试验预计将于 2019 年上半年开始。该药物已获得食品药物管理局（FDA）的快速通道指定。

预计老化将对几乎所有部门（包括医疗保健部门）产生深远的社会、经济和政治影响。由于老年人口的增加，需要长期照护的各种疾病的发生率将会增加。此外，中国和日本等具有大量开拓机会的国家老年人口的增加预计将在预测期内推动市场成长。

吸烟人口的急剧增加是可能对市场成长产生正面影响的主要驱动因素之一。根据美国FDA 和疾病管制与预防中心 (CDC) 的数据，2018 年有超过 360 万名高中生和中学生是电子烟使用者。自去年以来，这个数字增加了150万人。电子烟的普及性有望带动IPF的发展。

特发性肺纤维化治疗市场报告亮点：

  • Pirfenidone占据市场主导地位，2024 年市占率将达到 43.0%。
  • 口服药物引领市场，2024年销售份额为69.3%。与注射疗法相比，Pirfenidone和尼达尼布可提高患者的依从性。
  • 2024年，医院药局的销售额占比最大，为62.9%。这是因为医院配备了先进的诊断工具，可以准确诊断和监测IPF，有利于及时开始治疗。
  • 2024年，美国将因其较高的市场渗透率和IPF认知度而处于领先地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章特发性肺纤维化治疗市场变数、趋势、范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章特发性肺纤维化治疗市场：药物类别的商业分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年按药物类别分類的市场规模、预测与趋势分析
  • Pirfenidone
  • 尼达尼布
  • 干扰素γ1b
  • 其他的

第五章特发性肺纤维化治疗市场：给药途径的商业分析

  • 2024 年及 2030市场占有率给药途径途径
  • 途径细分仪表板
  • 2018-2030 年按管理途径的市场规模、预测与趋势分析
  • 口服
  • 注射

第六章特发性肺纤维化治疗市场：通路业务分析

  • 2024 年及 2030 年分销通路市场占有率
  • 分销通路细分仪表板
  • 2018-2030 年按分销管道分類的市场规模、预测与趋势分析
  • 医院药房
  • 零售药房
  • 其他的

第七章特发性肺纤维化治疗市场：按药物类别分類的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Medicinova, Inc
    • Merck &Co., Inc.
    • Galapagos NV
    • Novartis AG
    • Fibrogen, Inc.
Product Code: GVR-3-68038-119-1

Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends:

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth.

Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).

An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period.

The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights:

  • Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.
  • Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared to injectable therapies.
  • Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.
  • U.S. led in 2024 due to high market penetration and high awareness pertaining to IPF

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Idiopathic Pulmonary Fibrosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Idiopathic Pulmonary Fibrosis Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Pirfenidone
    • 4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
  • 4.5. Nintedanib
    • 4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
  • 4.6. Interferon Gammato1b
    • 4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Idiopathic Pulmonary Fibrosis Treatment Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 5.5. Injectable
    • 5.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 6. Idiopathic Pulmonary Fibrosis Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Idiopathic Pulmonary Fibrosis Treatment Market: Regional Estimates & Trend Analysis by Drug Class, Route Of Administration, and Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Boehringer Ingelheim International GmbH
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Bristol-Myers Squibb Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medicinova, Inc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Galapagos NV
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Fibrogen, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global idiopathic pulmonary fibrosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 Global idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 U.S. idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Canada idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Mexico idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 UK idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Germany idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 France idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 France Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 38 Spain idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Denmark idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Japan idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 Japan idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 China idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 China idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 India idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 India idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Australia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Australia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 South Korea idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 South Korea idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Thailand idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Thailand idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Latin America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Latin America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Brazil idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Brazil idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Argentina idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 Argentina idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 UAE idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 UAE idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Kuwait idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Idiopathic pulmonary fibrosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and route of administration outlook (USD Million)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Idiopathic pulmonary fibrosis treatment market dynamics
  • Fig. 13 Idiopathic pulmonary fibrosis treatment market: Porter's five forces analysis
  • Fig. 14 Idiopathic pulmonary fibrosis treatment market: PESTLE analysis
  • Fig. 15 Idiopathic pulmonary fibrosis treatment market: Drug class segment dashboard
  • Fig. 16 Idiopathic pulmonary fibrosis treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 17 Pirfenidone market, 2018 - 2030 (USD Million)
  • Fig. 18 Nintedanib market, 2018 - 2030 (USD Million)
  • Fig. 19 Interferon Gammato1b market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Idiopathic pulmonary fibrosis treatment market: Route of administration segment dashboard
  • Fig. 22 Idiopathic pulmonary fibrosis treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 23 Oral market, 2018 - 2030 (USD Million)
  • Fig. 24 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 25 Idiopathic pulmonary fibrosis treatment market: Distribution channel segment dashboard
  • Fig. 26 Idiopathic pulmonary fibrosis treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 27 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Idiopathic pulmonary fibrosis treatment market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework